Pentoxiverine — Competitive Intelligence Brief

Pentoxiverine (pentoxyverine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central Nervous System Stimulant [EPC]. Area: Respiratory.

marketed Central Nervous System Stimulant [EPC] Sigma non-opioid intracellular receptor 1 Respiratory

Target snapshot

Pentoxiverine (pentoxyverine).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pentoxiverine TARGET	pentoxyverine		marketed	Central Nervous System Stimulant [EPC]	Sigma non-opioid intracellular receptor 1
Aricept	DONEPEZIL	Eisai	marketed	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01
Naftin	NAFTIFINE	Legacy Pharma	marketed	Allylamine Antifungal	Sigma non-opioid intracellular receptor 1	1988-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	marketed	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Gocovri	AMANTADINE	Endo	marketed	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1	1968-01-01
Aralen	CHLOROQUINE	Sanofi	marketed	Antimalarial	Sigma non-opioid intracellular receptor 1	1949-01-01
Amantadin	Amantadin	Centre Hospitalier Universitaire de Nice	marketed		Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central Nervous System Stimulant [EPC] class)

1. · 5 drugs in this class
2. Caraco · 1 drug in this class
3. Hikma · 1 drug in this class
4. Impax Labs · 1 drug in this class
5. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class
6. UCB · 1 drug in this class
7. University of Colorado, Denver · 1 drug in this class